Literature DB >> 8212154

Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors.

J Gossmann1, H G Kachel, W Schoeppe, E H Scheuermann.   

Abstract

Immunosuppression of recipients of renal transplants with azathioprine has been associated with two major side effects: hepatotoxicity and myelotoxicity, mainly in the form of leukopenia. Reports of isolated anemia in these patients have been rare. We now observed the development of severe anemia in 9 out of 11 renal transplant recipients whose immunosuppressive regimen was converted from cyclosporine plus prednisone to azathioprine plus prednisone. A significant (P = 0.001) drop in hematocrit (from 34 +/- 4% to 27 +/- 3%, mean +/- SD) and hemoglobin (from 11.6 +/- 1.3 g/dl to 9.5 +/- 1.0 g/dl) was found. Since a common variable of all these patients was their use of an angiotensin-converting enzyme (ACE) inhibitor as antihypertensive medication, we speculated that the combination of azathioprine and ACE blocker might be the reason for the anemia. We then compared 2 groups of 10 patients each who had been on azathioprine as their regular immunosuppressive agent and who did or did not take an ACE inhibitor. Hematocrit and hemoglobin were significantly (P = 0.01) lower in the group of patients taking ACE inhibitors (33 +/- 6% versus 41 +/- 5% and 11.5 +/- 2.0 g/dl versus 14.0 +/- 1.6 g/dl, respectively). Haptoglobin levels were also significantly (P = 0.05) lower in the ACE inhibitor group (116 +/- 65 mg/dl versus 210 +/- 114 mg/dl). Erythropoietin concentration in the serum and the reticulocyte index were slightly, but not significantly, higher in the ACE inhibitor group but the values were probably too low for their degree of anemia. Comparing hematological parameters of the patients in the ACE inhibitor group before and after beginning of the antihypertensive treatment confirmed a significant reduction of hematocrit and hemoglobin following therapy with an ACE inhibitor. Hematocrit fell from 41 +/- 7% to 36 +/- 6% and hemoglobin from 14.0 +/- 2.3 g/dl to 11.3 +/- 1.5 g/dl (P < 0.05 for both). We conclude that the combination of these two drugs should probably be avoided.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212154     DOI: 10.1097/00007890-199309000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial.

Authors:  Matthew R Weir; Lisa Gravens-Muller; Nadiesda Costa; Anastasia Ivanova; Wana Manitpisitkul; Andrew G Bostom; Clarissa J Diamantidis
Journal:  Transplantation       Date:  2015-05       Impact factor: 4.939

Review 2.  Comprehensive Care of the Lung Transplant Patient.

Authors:  Ayodeji Adegunsoye; Mary E Strek; Edward Garrity; Robert Guzy; Remzi Bag
Journal:  Chest       Date:  2016-10-08       Impact factor: 9.410

3.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 4.  Understanding renal posttransplantation anemia in the pediatric population.

Authors:  Paul Joseph Galutira; Marcela Del Rio
Journal:  Pediatr Nephrol       Date:  2011-11-16       Impact factor: 3.714

Review 5.  Clinical pharmacology and pharmacogenetics of thiopurines.

Authors:  Srikumar Sahasranaman; Danny Howard; Sandip Roy
Journal:  Eur J Clin Pharmacol       Date:  2008-05-28       Impact factor: 3.064

6.  Prevalence and management of post-transplant anemia in long-term follow-up of Chinese kidney transplant recipients: a single-center report.

Authors:  Zhixian Wu; Junqi Guo; Lianming Liao; Weizhen Wu; Shunliang Yang; Jianming Tan
Journal:  Eur J Med Res       Date:  2013-11-15       Impact factor: 2.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.